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Abstract
The GLI (GLI1/GLI2) transcription factors have been implicated in the development and progression of prostate cancer
although our understanding of how they actually contribute to the biology of these common tumours is limited. We
observed that GLI reporter activity was higher in normal (PNT-2) and tumourigenic (DU145 and PC-3) androgen-
independent cells compared to androgen-dependent LNCaP prostate cancer cells and, accordingly, GLI mRNA levels were
also elevated. Ectopic expression of GLI1 or the constitutively active DNGLI2 mutant induced a distinct cobblestone-like
morphology in LNCaP cells that, regarding the former, correlated with increased GLI2 as well as expression of the basal/
stem-like markers CD44, b1-integrin, DNp63 and BMI1, and decreased expression of the luminal marker AR (androgen
receptor). LNCaP-GLI1 cells were viable in the presence of the AR inhibitor bicalutamide and gene expression profiling
revealed that the transcriptome of LNCaP-GLI1 cells was significantly closer to DU145 and PC-3 cells than to control LNCaP-
pBP (empty vector) cells, as well as identifying LCN2/NGAL as a highly induced transcript which is associated with hormone
independence in breast and prostate cancer. Functionally, LNCaP-GLI1 cells displayed greater clonal growth and were more
invasive than control cells but they did not form colonies in soft agar or prostaspheres in suspension suggesting that they
do not possess inherent stem cell properties. Moreover, targeted suppression of GLI1 or GLI2 with siRNA did not reverse the
transformed phenotype of LNCaP-GLI1 cells nor did double GLI1/GLI2 knockdowns activate AR expression in DU145 or PC-3
cells. As such, early targeting of the GLI oncoproteins may hinder progression to a hormone independent state but a more
detailed understanding of the mechanisms that maintain this phenotype is required to determine if their inhibition will
enhance the efficacy of anti-hormonal therapy through the induction of a luminal phenotype and increased dependency
upon AR function.
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Introduction
Prostate cancer (PCa) is the most common cancer in men and
although tumours initially respond well to anti-hormonal treat-
ment, the fact that many tumours acquire resistance to this form of
therapy provides a major obstacle in treating advanced forms of
the disease. Although the precise factors that initiate PCa remain
unclear, numerous studies have described genetic lesions and
aberrant signalling mechanisms that may contribute to tumour
formation and progression, and those that help confer androgen
independence are of particular interest as they may represent
novel targets for therapeutic intervention (reviewed in [1]).
As with many tumour forms, the role of cancer stem cells (CSC)
has received considerable attention in PCa biology, particularly
with regard to tumour initiation but also progression and
metastatic spread (reviewed in [2]). As prostate tumours display
a predominantly luminal phenotype including AR expression, they
are thought to derive from luminal secretory cells. However, based
upon CD profiling and cytokeratin expression, basal-like charac-
teristics have been identified in primary tumours and may be
increased in metastatic and hormone-refractory tumours [3,4].
Furthermore, basal/stem-like cells isolated from both primary
tumours and cancer cell lines display greater tumourigenicity in
mouse xenograft experiments [5,6,7,8,9,10]. In contrast, Vander
Griend et al [11] proposed that the cancer-initiating cell may be
an intermediate AR-expressing cell that ‘‘acquires stem-like
activity’’ and the heterogeneity of PCa is further highlighted by
studies of mouse models: Wang et al [12] described a rare luminal
stem cell population (expressing Nkx3-1) that can give rise to
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tumours whereas Lawson et al [13] found that basal epithelial stem
cells were transformed more efficiently.
Hedgehog (HH) signalling represents a major developmental
pathway that is implicated in the formation and progression of
numerous tumour types including those of the skin, breast,
pancreas, brain and lung. HH signalling, principally mediated by
the downstream GLI (referring to both GLI1 and GLI2)
transcription factors, is linked to tumourigenesis through the
regulation of diverse mechanisms such as proliferation, differen-
tiation, apoptosis, migration/invasion and the maintenance of
CSC populations (reviewed in [14,15,16]).
Recent studies have described activation of HH signalling in
PCa although the results have often been conflicting and the
mechanism(s) by which GLI contribute to neoplasia are not well
understood (reviewed in [17,18]). For example, several studies
have advocated that increased epithelial GLI1 expression
promotes tumour formation [19,20,21]. In contrast, Fan et al
[22] observed no significant difference in SHH or GLI1 mRNA
levels between tumour and zone matched benign tissue and, more
significantly, that GLI1 was expressed in the stromal, but not
epithelial, component of BPH and PCa. Regarding the more
advanced disease state, high levels of SHH protein and GLI1
mRNA have been described in metastatic samples and DHH,
GLI1 and GLI2 have been linked with transformation to a
hormone-refractory state [21,23,24,25]. Moreover, recent studies
have established a link between HH/GLI and AR signalling in the
androgen-dependent (AD), luminal epithelial LNCaP prostate
cancer cell line and demonstrated that GLI1 maintains cell
viability in the absence of AR activity [25,26,27,28].
Here we show that high GLI activity is observed in androgen-
independent (AI) DU145 and PC-3 epithelial prostate cancer cell
lines and that ectopic GLI1 promotes androgen independence in
LNCaP cells which correlates with their transformation to a
phenotype more characteristic of DU145 and PC-3 cells.
However, GLI suppression does not promote an AD phenotype
in DU145 or PC-3 cells. As such, early targeting of the GLI
oncoproteins may impede progression to a hormone independent
state, but this approach may not enhance the efficacy of anti-
hormonal therapy in tumour cells that have lost AR expression
and that are not dependent upon its signalling for their viability.
Results
Analysis of GLI expression in prostate cancer cells
To investigate a putative role for GLI in prostate cancer, we first
determined the level of GLI reporter activity in various prostate
cell lines. GLI reporter activity was higher in the AI DU145 and
PC-3 prostate cancer cell lines compared to the AD LNCaP
prostate cancer cell line and reporter activity was also higher in the
AI PNT-2 normal epithelial prostate cell line (Fig. 1A). Accord-
ingly, GLI1 and GLI2 mRNA expression was higher in all AI cell
lines compared to LNCaP cells (Fig. 1B). As such, we analysed the
effect of over-expressing GLI1 and the active DNGLI2 mutant
upon LNCaP cell biology. The most striking effect of ectopic GLI1
(eGLI1) and DNGLI2 related to cell morphology: in contrast to
the characteristic spindle-like morphology of parental or control
LNCaP-pBP (empty vector) cells, within a few days post-
transduction cells/colonies with a cobblestone-like morphology
were evident in LNCaP cells over-expressing eGLI1 or DNGLI2
(Fig. 1C). After drug selection, both LNCaP-GLI1 and LNCaP-
DNGLI2 cells had completely transformed adopting a morphology
reminiscent of PNT-2 or DU145 cells (refer Fig. 5A to view the
fully transformed morphology). Ectopic GLI1 and DNGLI2
protein activity was confirmed by induction of PTCH1 mRNA
(Fig. 1D). In addition, endogenous GLI2 mRNA was induced in
LNCaP-GLI1 cells whereas, unexpectedly, endogenous GLI1
mRNA was suppressed in LNCaP-DNGLI2 cells revealing that the
morphological change may be mediated by GLI2 (Fig. 1E). As
DU145 and PC-3 cells express high levels of both GLI1 and GLI2
compared to LNCaP cells (Fig. 1B), we chose to further investigate
the biology of LNCaP-GLI1 cells.
Initially, GLI reporter activity was measured in LNCaP-GLI1
cells and shown to be at a level comparable with PC-3 and DU145
cells (Fig. 1B, cf. columns 2–4). Subsequently, we addressed
whether the ability of eGLI1 to induce the cobblestone-like
morphology in LNCaP cells was through autonomous means or
whether or not this required paracrine/juxtacrine signalling
through molecules secreted by LNCaP-GLI1 cells. The morphol-
ogy of LNCaP cells expressing EGFP did not change when co-
cultured with LNCaP-GLI1 cells revealing that the cobblestone-
like morphology is induced autonomously (Fig. 1F). However, we
cannot discount the possibility that induction of the cobblestone-
like morphology is mediated through receptors that are expressed
in LNCaP-GLI1 cells (initially with a normal morphology) and
that subsequently bind to molecules secreted by the same (or other)
LNCaP-GLI1 cells acting through paracrine/juxtacrine signalling.
GLI1 confers androgen-independence to LNCaP cells
The expression of epithelial markers was investigated to
determine if the luminal phenotype of LNCaP cells was altered
by eGLI1: AR was strongly suppressed in LNCaP-GLI1 cells
whereas the basal/stem-like markers CD44, b1-integrin, DNp63,
and BMI1 were all increased (Fig. 2A); this was confirmed by
Western blot analysis for AR and CD44, with increased cell
surface expression of the latter confirmed by FACS (Figs. 2B and
C). Due to the uniform global shift in CD44 expression we chose
to employ the heterogenous population for further study.
Regarding androgen dependence, whereas exposure to the AR
inhibitor bicalutamide potently suppressed the proliferation of
LNCaP-pBP cells, the increased proliferative potential of LNCaP-
GLI1 cells was unaffected and this was verified by flow cytometry
(Figs. 2D, lanes 1–4 and E). Therefore, as determined by epithelial
marker expression and insensitivity to bicalutamide, these data
suggest that eGLI1 induces regression (or de-differentiation) of
LNCaP cells to a basal/stem-like form that is naturally
independent of AR signalling for viability.
To investigate this further, LNCaP-pBP, LNCaP-GLI1, DU145
and PC-3 cells were analysed by DNA microarrays: global array
profiling revealed that the transcriptome of LNCaP-GLI1 cells was
more similar to DU145 and PC-3 cells than to LNCaP-pBP cells
thus revealing the extent to which LNCaP-GLI1 cells have
changed phenotype (Fig. 3A). In direct comparison to LNCaP-
pBP cells, the expression of 260 transcripts differed more than 10-
fold (144 up and 116 down) in LNCaP-GLI1 cells (Fig. 3B and
Figures S1 and S2). Functional classification of these transcripts
produced 15 ontological groups including those associated with
tumour biology such as cell-cell adhesion, cell motility, EMT
(epithelial-mesenchymal transition) and hormone independence
(Figure S3); the latter group including LCN2 (lipocalin 2) and
CAV2 (caveolin 2) which were previously identified as part of a
common signature for hormone independence in breast and
prostate cancer [29]. The majority of the 144 increased transcripts
were expressed at similar levels in LNCaP-GLI1 cells when
compared to DU145 and/or PC-3 cells (,3-fold difference),
whereas the expression of 12 transcripts (including LCN2) was.3-
fold higher in LNCaP-GLI cells when compared to both cell types
(Figure S1 and Table 1). Reciprocally, of the 116 decreased
transcripts only one, MRPL23, was expressed .3-fold lower in
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LNCaP-GLI1 cells compared to both DU145 and PC-3 cells
(Figure S2).
As well as DNA microarray profiling, the extent of major
signalling pathway activation was assessed by Western blotting in
LNCaP-GLI1 cells. Hormone independence is associated with
EGFR pathway activation and although it has been established
that EGFR mRNA expression is not greatly increased in AI cell
lines ([29] and our microarray data), a strong increase in EGFR
protein expression was observed in LNCaP-GLI1 cells to a level
comparable with DU145 and PC-3 cells (Fig. 3C). ERK
(Extracellular signal-Regulated Kinase) activity was also increased
in LNCaP-GLI1 cells (Fig. 3C) and pharmacological inhibition of
EGFR or ERK suppressed their high proliferative potential
(Fig. 2D, cf. columns 1, 3, 5 and 6). Regarding AKT, although
increased activity is associated with mutational inactivation of
PTEN in LNCaP cells [30,31,32], eGLI1 reduced it to a level
comparable with DU145 cells suggesting that there are mecha-
nism(s) that could be exploited to obviate loss of this important
tumour suppressor gene (Fig. 3C). Regarding the cytoskeleton,
LNCaP-GLI1 cells displayed an increase of MLC2 (myosin light
chain 2) phosphorylation that was similar to both DU145 and PC-
3 cells (Fig. 3C and data not shown). MLC2 regulates the actin
cytoskeleton (including stress fibre formation) and is itself regulated
by MLCK (myosin light chain kinase) and ROCK (Rho-associated
kinase); exposure to the ROCK inhibitor Y27632 but not the
MLCK inhibitor ML-7 reduced MLC2 phosphorylation although
this did not reverse the cobblestone-like morphology of LNCaP-
GLI1 cells (Fig. 3D and unpublished observations). In summary,
these data further demonstrate the extent to which LNCaP-GLI1
cells resemble DU145 and PC-3 cells.
LNCaP-GLI1 cells do not display anchorage-independent
growth
HH/GLI signalling regulates normal and cancer stem cell
populations and recent studies have described how EMT is an
inherent trait of such cells [15,16,33]. Interestingly, despite their
cobblestone-like morphology, the results of the microarray
revealed that eGLI1 induces EMT in LNCaP cells (Figure S3).
Indeed, decreased E-Cadherin and increased vimentin expression
was confirmed by Western blotting, although this was not
dependent upon EGFR or MEK-ERK signalling [34] (Fig. 4A).
Accordingly, LNCaP-GLI1 cells were highly invasive through a
MatrigelTM substrate (Fig. 4B) and they also displayed greater
clonal growth when seeded at low density (Fig. 4C). However,
despite the expression of ‘stemness’ markers (including CD44, b1-
integrin and BMI1), EMT and greater clonal growth (Figs. 2A, 4A
and 4C), unlike control cells LNCaP-GLI1 cells did not form
prostaspheres in suspension or colonies in soft agar (Fig. 4D). To
address the possibility that LNCaP-GLI1 cells do not proliferate in
3-D culture because they are not able to differentiate towards a
luminal phenotype (i.e. because of constitutive eGLI1 expression),
DU145 cells were also cultured under the same conditions. No
colonies were observed in either assay with DU145 cells suggesting
that AR2 cells are poorly clonogenic in anchorage-independent in
vitro culture systems (data not shown); this is supported by
Thiyagarajan et al [35] who observed that DU145 (and PC-3
cells) were much less proliferative in soft agar compared to LNCaP
cells although some colony growth was evident in their study.
GLI suppression does not promote a luminal-like
phenotype in androgen-independent prostate cancer
cells
Finally, we sought to determine if targeted suppression of GLI
was sufficient to reverse the transformed phenotype of LNCaP-
GLI1 cells or to induce a luminal-like phenotype in DU145 or PC-
3 cells. Transfection of LNCaP-GLI1 cells with GLI1 or GLI2
siRNA did not influence the morphology of LNCaP-GLI1 cells
nor was there any change in the expression of DNp63 or AR
mRNA (Figs. 5A–C and Figure S4A); this indicates that the
phenotypic conversion induced by eGLI1 in LNCaP cells is
irreversible and that maintenance of the AI phenotype is not
dependent upon GLI2. Regarding DU145 and PC-3 cells, the
efficacy of double GLI1/GLI2 knockdowns was confirmed by a
decrease of GLI reporter activity but there was no change in cell
morphology nor was there any change in the expression of DNp63
or AR mRNA (Figs. 5D–F, Figure S4B and unpublished
observations). We also employed the GLI inhibitor GANT61
(30 mM) [36] but this was less efficient at suppressing GLI reporter
activity than RNAi (data not shown). As such, although AI
prostate cancer cells display high GLI mRNA expression and
activity and eGLI1 is able to promote an AI phenotype in LNCaP
cells, GLI suppression does not promote a luminal-like and AD
phenotype in AI prostate cancer cells.
Discussion
The role of HH signalling has proven contentious in PCa biology;
this includes debate as to whether or not the pathway contributes to
primary tumour formation as well the actual mode of signalling
(autocrine or paracrine). In addition, there has been conflicting data
as to whether or not GLI expression is mediated through canonical
or non-canonical pathways in PCa cell lines (reviewed in [18]). We
have not addressed the nature of GLI regulation but have shown
that the AI cell lines PNT-2, DU145 and PC-3 display higher levels
of GLI mRNA than the AD LNCaP prostate cancer cell line and
this correlates with increased GLI reporter activity (Figs. 1A and B).
The fact that GLI1 expression was comparable between normal
PNT-2 cells and tumourigenic DU145 and PC-3 cells was
unexpected but in contrast to Karhadkar et al [21], we also found
that GLI1 mRNA was strongly expressed in commercial primary
prostate basal epithelial cells (PrECs), though a faithful comparison
to the cell lines used in this study was not possible because PrECs are
cultured in specialist medium that does not contain serum (S.K.N.
and G.W.N., unpublished). Despite these observations, at the
protein level GLI1 is rarely detected in the basal layer of normal
human prostate tissue whereas expression is more prevalent in
hyperplastic basal cells and carcinomas [20]. As such, in a manner
akin to GLI2 regulation [37], although GLI1 mRNA expression is
constant between normal and tumourigenic cells, the protein may
be stabilised in the latter (possibly through Fused [38]) and this,
along with the GLI2, could account for the increase in GLI reporter
activity.
Figure 1. GLI activity is high in androgen-independent cell lines. (A) Analysis of GLI luciferase reporter activity in various androgen-
independent cell lines and in comparison to the androgen-dependent LNCaP cell line. (B) Quantitative PCR analysis of GLI1 and GLI2 mRNA levels in
the androgen-independent cell lines and in comparison to LNCaP cells (C) Cobblestone-like cells/colonies emerge in LNCaP cells with ectopic GLI1 or
DNGLI2 expression (denoted by arrows). (D) qPCR analysis of PTCH1 mRNA expression in LNCaP-GLI1 and LNCaP-DNGLI2 cells. (E) qPCR analysis of
GLI2 mRNA expression in LNCaP-GLI1 cells and GLI1 mRNA expression in LNCaP-DNGLI2 cells. (F) The morphology of LNCaP cells expressing EGFP
does not change when co-cultured with LNCaP-GLI1 cells.
doi:10.1371/journal.pone.0020271.g001
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Our data suggests that GLI1 induces androgen-independence in
LNCaP cells through its ability to induce a basal-like phenotype
that is associated with basal cell populations and that is naturally
independent of AR activity; this is supported by reduced AR
expression combined with an increase of numerous basal/stem-
like markers. Chen et al [26] also described a role for GLI1 in
promoting AI growth in LNCaP cells but this was not associated
with reduced AR expression and may reflect the fact that eGLI1
expression was lower in their system as determined by a lesser fold-
increase of GLI1 reporter activity. Although our studies were
performed on a heterogenous cell population, the phenotype was
uniform and we have not been able to isolate LNCaP-GLI1 clonal
lines that maintain normal LNCaP morphology indicating that
retroviral eGLI1 promotes an ‘all or nothing’ response, but as the
level of GLI reporter activity was comparable with DU145 and
PC-3 cells this indicates that our system has biological relevance.
How eGLI1 mediates the transformation of LNCaP cells has not
been elucidated but may involve multiple mechanisms: eGLI1
inhibition of AR signalling alone is unlikely to initiate the
phenotypic change but, combined with its ability to sustain cell
viability in the absence of AR signalling [27,28], this may
compound the effects of its principal role as a transcriptional
activator.
As noted above, eGLI1 increased total GLI activity in LNCaP
cells to a level comparable with DU145 and PC-3 cells.
Microarray profiling revealed that the transcriptome of LNCaP-
GLI1 cells was similar to both DU145 and PC-3 cells with the
expression of certain genes comparable to one or both cell lines.
This probably reflects the genotype of each cell and the fact that
GLI activity and target gene activation are influenced by signalling
enzymes (including ERK and AKT) that are differentially
activated in each cell type [39,40,41]. Intriguingly, Nadiminty et
al [42] recently listed a set of 50 target genes induced by NF-kB2
in LNCaP cells, 15 of which are present in our list of 144 genes
induced .10-fold by eGLI1 in LNCaP cells (including LCN2)
suggesting that NF-kB2 activation is one of the mechanisms
through which eGLI1 elicits its effect in LNCaP cells (Figure S1,
transcripts highlighted in red).
Regarding the expression of transcripts that are highest in
LNCaP-GLI1 cells (Table 1), ABCC3 is of particular interest
because it encodes a protein that belongs to the ABC (ATP-
Binding Cassette) family of transporters that confer drug resistance
and that are highly expressed in normal and cancer stem cells
(reviewed in [43]). HH/GLI1 signalling has been shown to
regulate the expression of Pgp (ABCB1) and BCRP (ABCG2) in
various cancer cell lines including PC-3 [44]. In addition, the
SMO inhibitor GDC-0449 was recently shown to inhibit the drug
resistance properties of Pgp and and BCRP [45]. The shuttle/
transport protein lipocalin 2 (LCN2) is also of particular interest:
lipocalin 2 was identified as one half of a complex with matrix
metalloproteinase MMP-9 that is elevated in the urine of cancer
patients (notably breast, bladder, pancreas and prostate) [46,47],
and it also forms part of a common gene signature for hormone
independence in breast and prostate cancer [29]. Functionally,
lipocalin 2 protects MMP-9 from degradation and recently it has
been shown to promote EMT by modulating ERa (oestrogen
receptor alpha) and SLUG expression in MCF-7 cells. In addition,
lipocalin 2 negates the response of MCF-7 cells to oestrogenic
stimulation [48]. GLI1 also represses ERa in MCF-7 cells and
negates their response to oestrogenic stimulation as well as
promoting hormone independence [49]. These studies provide
evidence for functional overlap between GLI1 and lipocalin 2 in
breast cancer and, accordingly, the expression of both proteins is
associated with the ER2 phenotype [49,50,51,52]. Similarly,
although the tight junction protein claudin 1 (CLDN1) is often
decreased in breast tumours [53,54,55], high expression has been
described in ER2 tumours [56,57]. In the prostate, claudin1
expression is high in the basal layer of benign tissue and its
expression decreases with increasing tumour aggressiveness
[58,59]. A similar pattern of expression has also been described
for the actin-binding protein transgelin (TGLN) [60]; although this
may appear anomalous, it is feasible that these proteins are
expressed at high levels in a small population of basal-like CSCs
that are not easily detected by immunohistochemistry in tumours
that display a predominantly luminal (AR+) phenotype. Indeed,
transgelin is more highly expressed in the CD44+ fraction of
DU145 and LNCaP cells [61] and some evidence of increased HH
signalling has been described in an invasive subpopulation of
DU145 cells that express higher levels of CD44 as well as the stem
cell marker NANOG [62].
Although HH/GLI1 signalling modulates CSC biology in
various tissues, defining its role in PCa is complicated by the fact
that cancer-initiating cells may stem from AR2 (basal) or AR+
(intermediate/luminal) populations [5,6,7,8,11,12,13]. If PCa
arises from basal/stem-like cells then based upon the results
presented here, theoretically they would express high GLI levels.
Conversely, if PCa arises from luminal (or intermediate) cells that
express AR then they would be expected to express low or absent
levels of GLI. This study has not addressed the role of GLI in
tumour initiation but its expression is increased in hyperplastic
basal cells that co-express CD44 and p63 [20]. Interestingly, the
same authors demonstrated GLI expression in localised prostate
cancer; this may be unexpected as primary tumours are considered
to display a predominantly luminal phenotype (i.e. p632/AR+) but
this probably reflects lower GLI activity compared to more
aggressive tumours. However, a meta-analyses of microarray
datasets has shown that a considerable number of localised
prostate tumours display a gene expression profile which is
indicative of hormone-independence and reduced AR expression
[29]. Indeed, it would be interesting to determine if GLI
expression was evident in these datasets although they may have
been subject to the same technical limitations that are discussed at
the end.
Less equivocal is the role of GLI in advanced PCa: high levels of
GLI1 mRNA have been described in metastatic tumours and both
GLI1 and GLI2 have been linked with androgen-independence
[21,23,24,25,27]. The basal cytokeratin K5 is expressed in
metastatic tumours and this is increased in tumours subject to
androgen deprivation as well as those that are hormone-refractory
[4]. Moreover, CD profiling and expression studies have shown
that basal cells are present in advanced/metastatic tumours
[3,63,64]. Intriguingly, Liu et al [63] identified the EMT marker
Figure 2. GLI1 induces an androgen-independent phenotype in LNCaP cells. (A) qPCR analysis of epithelial marker expression in LNCaP-
GLI1 cells relative to LNCaP-pBP cells (n.b. the data is presented as natural logarithms so the relative induction of CD44 is almost 7000-fold). (B)
Western blot analysis of AR and CD44 expression in LNCaP-pBP, LNCaP-GLI1 and DU145 cells (arrows denote CD44 isoforms common to LNCaP-GLI1
and DU145 cells). (C) FACS analysis of CD44 expression in LNCaP-pBP and LNCaP-GLI1 cells. (D) Proliferation assay to compare and to determine the
effect of bicalutamide upon the proliferation rate of LNCaP-pBP and LNCaP-GLI1 cells as well as the effect of AG1478 (EGFR inhibitor) and U0126 (MEK
inhibitor) upon the latter. (E) Analysis of the cell cycle by flow cytometry in LNCaP-pBP and LNCaP-GLI1 cells exposed to bicalutamide.
doi:10.1371/journal.pone.0020271.g002
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vimentin as part of a basal cDNA signature in metastatic prostate
tumours. Combined with the fact that EMT is synonymous with
CSC biology [33] and that prostate stem/progenitor cells often
express basal markers (reviewed in [2]), this suggests that there is
synergy between EMT and the basal phenotype in prostate CSC
biology and these phenomena may be linked through HH/GLI
signalling.
Regarding the mechanisms that control GLI expression in
advanced PCa, as well as canonical HH signalling [25], GLI may
be regulated by TGF-b (via Smad3) [65]. Inhibition of TGF-b or
Smad3 has been shown to suppresses the growth and metastasis of
AI tumours in Nude mice (but not tumour incidence) and, as for
GLI, Smad3 is expressed at considerably higher levels in DU145
cells compared to LNCaP cells [66,67]. Therefore, TGF-b/Smad3
signalling may, in part, account for increased GLI expression in
advanced PCa and this also correlates with the fact that TGF-b is
associated with EMT and CSC biology [33]. Based upon the fact
that GLI reporter activity was high in DU145 and PC-3 cells and
that eGLI1 induced an AI phenotype in LNCaP cells, we had
surmised that GLI inhibition may induce an AD phenotype in
DU145 and PC-3 cells through increased AR expression.
Surprisingly, neither eGLI1 nor GLI2 suppression reversed the
phenotype of LNCaP-GLI1 cells; although we cannot discount the
possibility that protein expression was not sufficiently suppressed,
this suggests that the transformation is irreversible or that once the
process has occurred it is no longer dependent upon GLI activity
and this is supported by the fact that GLI suppression did not
influence the phenotype of DU145 or PC-3 cells as determined by
marker gene expression (Fig. 5F). A global screening approach
may be required to determine if it is possible for DU145 or PC-3
cells to trans-differentiate towards a luminal phenotype that is
dependent upon AR function but this may not be possible for the
former as loss of AR expression is associated with promoter
methylation (Sasaki et al, 1992). However, this approach may be
viable for PC-3 cells as well as those hormone refractory tumours
where loss of (or reduced) AR expression is not associated with
promoter methylation [68,69]. MicroRNAs provide an attractive
target for further investigation as they can regulate multiple genes,
including AR, and are associated with stem cell biology, tumour
biology and hormone independence [70,71,72,73,74,75]. This will
be supported by delineating the mechanisms through which the
GLI oncoproteins promote hormone independence and as these
may be common to the pathogenesis of breast and prostate cancer
such investigations are clearly warranted. Moreover, the fact that
GLI inhibition has been shown to negatively influence the
proliferation and clonogenic/tumourigenic potential of prostate
cancer cell lines as well as increasing their sensitivity to cancer
drugs enhances their attractiveness as target proteins for
therapeutic intervention [19,23,35].
Finally, in this study we found that the microarray failed to
detect GLI1 or GLI2 as highly expressed transcripts in LNCaP-
GLI1, DU145 or PC-3 cells. Indeed, from the normalised data the
expression of GLI1 was constant between all four cell lines
analysed and GLI2 was only slightly increased in LNCaP-GLI1
cells (2.24-fold), DU145 cells (2.95-fold) and PC-3 cells (2.71-fold)
which does not correlate with the qPCR data (Fig. 1B). The GLI1
probe sequence corresponds to a region within the last exon of
GLI1 (NM_005269.2) and should detect both eGLI1 and
endogenous GLI1 in all cell lines. In addition, the lack of signal
is unlikely to be due to the presence of GLI1 splice variants as
these are N-terminal [76,77]. Regarding GLI2, the probe
sequence corresponds to the non-coding region of the last exon
Figure 3. Ectopic GLI1 induces global changes in the gene expression profile of LNCaP cells. (A) A statistical comparison of global gene
expression profiles to determine the percentage of transcripts that are expressed at significantly different levels in LNCaP-pBP, DU145 and PC-3 cells
compared to LNCaP-GLI1 (Pearson correlation co-efficient $0.7, p,0.05) (B) Heat map denoting transcripts in LNCaP-GLI1 cells where the change in
expression is both .10-fold and highly significantly different when compared to LNCaP-pBP cells (student’s t-test, p,0.01): left panel lists increased
genes, right panel lists decreased genes and DU145 and PC-3 cells are shown for comparison (* denotes transcript variants of the same gene). (C)
Western blot analysis comparing the expression of certain signalling proteins between LNCaP-pBP and LNCaP-GLI1 cells with DU145 and PC-3 lysates
included for comparison. (D) Phosphorylation of the cytoskeletal protein MLC2 is mediated by ROCK in LNCaP-GLI1 cells (n.b. the antibody for total
MLC did not work in our hands).
doi:10.1371/journal.pone.0020271.g003
Table 1. Highly expressed transcripts in LNCaP-GLI1 cells.
Symbol Accession No. Fold change v LN-pBP Fold change v DU145 Fold change v PC-3 Functional Group (Figure S2)
ABCC3 NM_003786.2 98.30 13.122 3.669 ATP and glucose metabolism
CLDN1 NM_021101.3 65.57 4.865 15.793 Cell-cell adhesion, EMT
LCN2 NM_005564.3 55.32 287.939 6.102 EMT, Hormone independence
SMOX-4 NM_175842.1 52.23 3.106 4.033 None
TAGLN NM_003186.3 19.49 9.323 28.077 Cytoskeletal regulation
SMOX-2 NM_175840.1 19.30 3.047 3.529 None
SUSD2 NM_019601.3 15.83 19.827 10.819 None
TUBB2B NM_178012.3 10.87 6.804 8.643 ATP and glucose metabolism, Rho
GTPase signalling
NKD2 NM_033120.2 10.49 7.649 21.551 None
HCP5 NM_006674.2 10.33 3.221 5.446 None
APOE NM_000041.2 10.04 8.952 4.633 Angiogenesis, Apoptosis regulation,
Cytoskeletal regulation
ARMCX2 NM_177949.1 10.01 4.019 5.739 None
doi:10.1371/journal.pone.0020271.t001
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(NM_005270.4) and should also detect the known splice variants
[78,79,80]. As such, failure to capture GLI1 or GLI2 mRNA
appears to be a technical issue and it is likely that the expression
level of these genes has been misrepresented in other datasets
generated with the Illumina platform.
Materials and Methods
Vector construction
Human GLI1 encoding cDNA was amplified by standard PCR
with Pfu Turbo DNA Polymerase (Stratagene) and pBluescript-
GLI1 (a gift from Kenneth Kinzler) as the template: the primers
contained 59 phosphate groups (Forward, 59-CTCTGAGACGC-
CATGTTCA-39 and Reverse, 59-GATTCCCTACTCTTTAG-
GCA-39). The amplicon was cloned into pBabePuro blunted at the
Sal1 site to create pBP-GLI1; the integrity of the coding region
was verified by sequencing. DNGLI2b coding cDNA was isolated
from pcDNA4/TO-HisDNGLI2b (Regl et al, Oncogene 2004) by
Pme1 digestion and cloned into pBabePuro blunted at the Sal1 site
to create pBP-DNGLI2b. The DNGLI2b mutant is lacking the
first 328 amino acids and is highly transcriptionally active
compared to the wild-type GLI2b protein [79].
Cell culture and retroviral transduction
The prostate cancer cell lines LNCaP, DU145 and PC-3 were
obtained from the European Collection of Cell Cultures (through
Sigma-Aldrich) and normal prostate epithelial PNT2 cells were
kindly provided by Norman Maitland (University of York) [81].
All cells were maintained in RPMI 1640 medium supplemented
with 10% FBS, L-Glutamine (2 mM), penicillin (50 U/ml) and
streptomycin (50 mg/ml) (all Lonza). Amphotropic retroviral
particles harbouring pBabePuro (empty vector), pBP-GLI1 or
pBP-DNGLI2 were created as described previously [82] using the
Phoenix packaging cell line obtained from the Nolan Laboratory
(http://www.stanford.edu/group/nolan/retroviral_systems/phx.
html). To create the LNCaP-pBP, LNCaP-GLI1 and LNCaP-
DNGLI2 stable cell lines, parental LNCaP cells were exposed to
the corresponding viral particles in the presence of polybrene
(5 mg/ml) and centrifuged at 3006g for 1 hr at 32uC.
Subsequently, the cells were allowed to recover for 72 hrs prior
Figure 4. LNCaP-GLI1 cells display some stem-like characteristics. (A) Western blot analysis comparing expression of the EMT markers E-
cadherin and vimentin between LNCaP-GLI1 and LNCaP-pBP cells (n.b. the decrease of E-cadherin in LNCaP-GLI1 cells is partially reversed in the
presence of the EGFR inhibitor AG1478 and to a lesser extent the MEK inhibitor U0126). (B) Transwell invasion assay comparing the invasive potential
of LNCaP-pBP and LNCaP-GLI1 cells through a Matrigel substrate. (C) Clonogenicity assay assessing the colony-forming ability of LNCaP-pBP and
LNCaP-GLI1 cells when seeded at low density. (D) Anchorage-independent growth is observed in LNCaP-pBP cells but not LNCaP-GLI1 cells (top panel
- soft agar colony assay; bottom panel - prostasphere assay).
doi:10.1371/journal.pone.0020271.g004
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to selection with puromycin (1 mg/ml) for up to 1 week and
beyond the time when all the control (non-transduced) cells had
expired.
Reporter assay
Cells were seeded at a density of 2,000 cells/cm2 in triplicate (6-
well plates) and transfected 48 hr post-seeding with 1 mg of the
GLI firefly luciferase reporter pGL3-6GBS [83] and 1 mg of a
pCMV-Renilla normalisation vector using 3 ml of Fugene6
(Roche). Cells were harvested 24 hr post-transfection and analysed
for luciferase activity using the Dual Luciferase Assay Kit
(Promega) and a FLUOStar OPTIMA reader (BMG Labtech)
(n = 3).
Proliferation and clonogenicity assays
LNCaP-pBP and LNCaP-GLI1 cells were seeded at a density of
500 cells/cm2 and exposed to bicalutamide (10 mg/ml), AG1478
(1 mM), UO126 (5 mM) or vehicle (DMSO) 24 hr post-seeding.
Fresh drug/media was added after another 72 hr and the cells
were trypsinised and counted 7 days post-seeding using a Casy 1
counter (Sharfe System GmBH) (n = 3). For clonal growth,
LNCaP-pBP and LNCaP-GLI1 cells were seeded at a density of
50 cells/cm2 in triplicate and cultured for 10 days prior to fixing in
3% paraformaldehyde and staining with crystal violet (n = 3).
Western Blotting
Protein lysates were prepared as described previously [82] with
separation and transfer to nitrocellulose membrane performed
according to standard protocols. In summary, cells were seeded at
a density of 7000/cm2 and harvested 72 hr post-seeding: where
indicated pharmacological agents including AG1478 (1 mM),
UO126 (5 mM), ML-7 (10–20 mM) and Y27632 (10–20 mM) were
added 24 hr before harvesting. Primary antibodies used were:
CD44 (eBiosciences); GLI1 C-18 and EGFR SC-03 (Santa Cruz
Biotechnology); AR, E-cadherin and vimentin (BD Biosciences);
ERK (also used as a loading control), phospho-ERK (E10), AKT,
phospho-AKT (Ser473) and phospho-MLC2 (Cell Signalling
Technology). Secondary HRP-linked antibodies were obtained
commercially (DAKO) and immunodetection performed with
ECL+ reagent (GE Healthcare).
Quantitative polymerase chain reaction
Total RNA was isolated using the RNeasy Plus Mini Kit
(Qiagen, Valencia, CA) with 3 mg of RNA used to prepare 30 ml of
cDNA using the SuperscriptH First Strand Synthesis System
(Invitrogen Life Science). Quantitative polymerase chain reactions
(qPCR) were performed with PlatinumTM SYBRH Green qPCR
Supermix (Invitrogen Life Science) and analysed on a Corbett
Rotor-Gene 3000. The melting curve graph of the PCR product
indicated that the data generated was from a single product and
confirmed by running on a 1% agarose gel. Relative induction
values (x) were calculated using the formula x= 22DDCT where Ct
represents the mean threshold cycle of replicate analyses, DCt
represents the difference between the Ct values of the target gene
and the reference gene GAPDH, and DDCt is the difference
between the DCt values of the target gene for each sample
compared to the DCt mean of the reference sample (LNCaP or
LNCaP-pBP). Primers used were 59-39: GLI1 F-GAAGACC-
TCTCCAGCTTGGA, R-GGCTGACAGTATAGGCAGAG;
GLI2 F-GGGTCAACCAGGTGTCCA, R-GATGGAGGGCA-
GGGTCAAGGA; PTCH1 F- ACTCGCCAGAAGATTGGAG-
A, R- TCCAATTTCCACTGCCTGTT; CD44 F-GTGATC-
AACAGTGGCAATGG, R-CCACATTCTGCAGGTTCCTT;
b1-Int F-GGGGTAATTTGTCCCGACTT, CATCTGCGAG-
TGTGGTGTCT; DNp63 F- GTCCCAGAGCACACAGACA,
R- GAGGAGCCGTTCTGAATCTG; Bmi1 F- CCAGGGC-
TTTTCAAAAATGA, R-CCGATCCAATCTGTTCTGGT; AR
F- TACCAGCTCACCAAGCTCCT, R-GCTTCACTGGGT-
GTGGAAAT; PSA F-CACAGCCTGTTTCATCCTGA, R-AG-
GTCCATGACCTTCACAGC and GAPDH F-GCCTTCC-
GTGTCCCCACTGC, R-GCTCTTGCTGGGGCTGGTGG.
Flow cytometry
For cell cycle analysis, 4000 cells/cm2 were seeded in a T-25
flask and exposed to bicalutamide (10 mg/ml) or vehicle (DMSO)
for the final 48 hrs before harvesting (96 hrs post-seeding).
Trypsinised cells were washed twice at 1200 RPM for 5 min in
PBS with the pellet then fixed in cold sterile 70% ethanol before
storing at 4uC overnight. Fixed cells were then washed 63 at
1200 RPM for 5 min in 5 ml PBS. During the third wash 100 ml
of cells from one of the cell lines was aliquoted separately to
calibrate the FACS machine. After washing, the pellet was re-
suspended in 300 ml of DAPI solution (10 mls of 0.1 mg/ml DAPI,
25 mls of 5.0 mg/ml RNase-A, 380 mls of 100 mM sodium citrate
in 485 mls PBS) and incubated in the dark for 30 min at RT.
DAPI-labelled cells were loaded on a BD FACS machine (LS-RII)
and analysed with DIVA software.
For FACS, cells were incubated with 10 ml of versene for
15 min at 37uC, neutralised with RPMI/10% FCS then
centrifuged at 1200 RPM for 5 min at RT. The cell pellet was
washed twice in PBS then incubated for 1 hr in the dark with
fluorescently-labelled CD44 antibody (14-0441, eBioscience)
diluted 1:500 in PBS. CD44-labelled cells were loaded on a BD
FACS machine (LS-RII) and analysed with DIVA software.
Gene expression and statistical analyses
Gene expression profiling was performed using a HumanHT-
12v4 BeadChip read by the HiScanSQ system (Illumina, Inc).
All samples were analysed in triplicate and the results were
normalised to the LNCaP-pBP transcriptome using Bead-
StudioH software (Illumina, Inc): the raw data has been deposited
with GEO (Accession No.: GSE27231) and is MIAME
compliant. Normalised data was filtered for significant genes
(student’s t-test; p,0.01) with a .10-fold expression difference
(6) using custom designed software plugged in to Excel.
Significant genes were grouped using DAVID 6.7 software
[84,85] and further verified by consensus clustering using
GenePattern software [86]. A direct global array comparison
of the LNCaP-GLI1 transcriptome versus the LNCaP-pBP,
DU145 and PC-3 transcriptomes was done using the Pearson
correlation matrix (p,0.05) using MeV v.4.5.1 software (TM4,
Microarray Software Suite) [87,88].
Figure 5. GLI suppression does not induce a luminal-like phenotype in androgen-independent cells. (A) The transformed morphology of
LNCaP-GLI1 cells does not reverse upon transfection with GLI1 or GLI2 siRNA. (B) qPCR analysis of GLI1 and GLI2 mRNA in LNCaP-GLI1 cells transfected
with GLI1 or GLI2 siRNA. (C) RT-PCR analysis of DNp63 and AR mRNA in LNCaP-GLI1 cells transfected with GLI1 or GLI2 siRNA. (D) qPCR analysis of GLI1
and GLI2 mRNA in DU145 and PC-3 cells transfected with GLI1 and GLI2 siRNA. (E) GLI reporter activity is suppressed in DU145 and PC-3 cells
transfected with GLI1 and GLI2 siRNA (n.b. reporter activity may be influenced by GLI3 expression in PC-3 cells [17]). (F) RT-PCR analysis of DNp63 and
AR mRNA in DU145 and PC-3 cells transfected with GLI1 and GLI2 siRNA.
doi:10.1371/journal.pone.0020271.g005
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Transwell invasion and anchorage-independent assays
Cell invasion assays were performed over 72 hr using Matrigel-
coated (diluted 1:2 with RPMI 1640) polycarbonate filters
(Transwell, BD Biosciences). Cells (50,000 seeded) invading the
lower chamber were trypsinised and counted using a Casy 1
counter (Sharfe System GmBH) (n = 6). For soft agar growth, 2500
cells/ml were re-suspended in 0.4% agarose on a 1% agarose bed
(diluted in RPMI 1640/10% FCS) and cultured for up to 3 weeks
with medium covering the top layer being replaced every 3–4 days
(n = 3). For prostasphere growth, 500 cells/ml were re-suspended
in DMEM/F12 medium supplemented with B27 and N2
(Invitrogen) in non-adherent plates and cultured for up to 3 weeks
(n = 3).
RNA interference
7000 cells/cm2 were reverse-transfected with control siGLO
(Dharmacon) or siRNA targeting GLI1 (Ambion SilencerH Select
s5816) and/or GLI2 (Ambion SilencerH Select s5817) using the
Hiperfect (Qiagen) transfection reagent to produce a final
concentration of 30 nM; fresh medium was added 24 hr post-
seeding. RNA was isolated 96 hr post-seeding or cells were
transfected with pGL3-6GBS and pCMV-Renilla 72 hr post-
seeding prior to harvesting for luciferase activity 96 hr post-
seeding (n = 3).
Supporting Information
Figure S1 Excel worksheet with the raw expression data
of the positively regulated genes presented within the
left heat map of Fig. 3B. The transcripts additionally presented
in Table 1 are underlined and those that were identified as targets
of NF-kB2 [41] (see Discussion) are highlighted in red.
(TIF)
Figure S2 Excel worksheet with the raw expression data
of the negatively regulated genes presented within the
right heat map of Fig. 3B.
(TIF)
Figure S3 Mini heat maps denoting functional groups of
the genes presented in Fig. 3B and Figures S1 and S2.
(TIF)
Figure S4 qPCR analysis of DNp63 mRNA expression in
LNCaP-GLI1, DU145 and PC-3 cells.
(TIF)
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